Ziihera is a medicine used in adults to treat biliary tract cancer (cancer of the structures that store and transport bile) when the cancer has high levels of a protein called HER2, measured with a test called immunohistochemistry. High levels of HER2 help the tumour cells grow more quickly. Ziihera is used when the cancer is unresectable (cannot be removed by surgery) and is locally advanced (has spread to nearby tissues) or metastatic (has spread to other parts of the body) and has previously been treated with at least one other systemic cancer medicine. Systemic means that the medicine works throughout the whole body. Ziihera contains the active substance zanidatamab.
Therapeutic Indication
### Therapeutic indication Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2).
Therapeutic Area (MeSH)
ATC Code
L01FD07
ATC Item
xl 01 fd 07
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| zanidatamab | N/A | Zanidatamab |
EMA Name
Ziihera
Medicine Name
Ziihera
Aliases
N/ANo risk management plan link.
